SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels post-earnings selloff is centered on a weaker-than-expected Q4 outlook, with traders pointing to soft PC demand and manufacturing constraints despite a stronger Q3 showing; the Fab 28 disruption is also cited as a headwind. The community is split between dip-buyers calling the drop an overreaction and bearish traders focused on delayed growth, execution concerns, and analyst downgrades.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is drawing attention after strong quarterly results and an upbeat outlook failed to prevent a sharp drop, alongside an announced 8-for-1 split and a broader chip selloff. Traders debate whether the decline is profit-taking and market-wide pressure or a warning that memory pricing may be nearing a cyclical peak.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and outlook have sparked a sharp selloff, with traders focused on heavy AI infrastructure spending and negative free cash flow despite accelerating AWS growth. The debate is whether cloud demand and future returns justify the spending: some see the drop as overdone and are buying the dip, while others worry about cash burn and delayed payback.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits post-earnings selloff is centered on weaker-than-expected Q4 guidance, slowing user growth and declining Google search referrals, alongside plans to test a logged-in-only experience. Traders worry those changes could further reduce traffic and ad reach, while others view the drop as an overreaction to an otherwise strong quarter and see a buying opportunity.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is drawing attention after a reported major Binance security breach prompted a crypto selloff and renewed concerns about exchange security. Traders disagree over whether the incident signals broader risk to crypto or is limited to a centralized exchange, with some viewing the pullback as a buying opportunity and others warning of further declines.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led selloff following disappointing Intel guidance and Amazons heavy AI spending has intensified concerns that Big Techs capital expenditures may not deliver adequate returns, weighing on QQQ. Traders are split between calling it an AI-bubble unwind with further downside and viewing the decline as a buying opportunity or potential bounce.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention after a steep retreat from silvers January peak, with persistent selling and a break below the closely watched $50 area prompting traders to debate where support may form. Many expect further losses, while others see oversold conditions and are buying dips; explanations range from higher yields and profit-taking to unsubstantiated claims of market manipulation.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases quarterly results sparked debate: traders noted the headline profit beat but questioned its quality because much of it came from gains on crypto holdings while operating income and transaction revenue weakened. Concern over reports of a major Binance security breach and the resulting crypto-market pressure added to bearish sentiment, though some see Coinbase as a potential beneficiary because its own platform was not reported hacked.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias Q3 results and higher full-year revenue guidance are driving attention, with traders pointing to continued LUPKYNIS growth and profitability. Reactions are mixed: some call the report strong, while others question the lack of sequential sales growth and another earnings release without a call, alongside volatile trading.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results beat expectations and the company raised its delivery outlook as the R2 ramp gains traction, drawing bullish reactions from traders. The enthusiasm is tempered by frustration over muted share performance and concerns about continued losses, cash burn, and the path to profitability.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month

Equity

Cel-Sci priced the share offering at $1, a 7.4% discount from the stock’s previous close.

Why DID CVM Shares Rally Over 7% Today?

According to a filing with the U.S. Securities and Exchange Commission, CEO Kersten Geert R. purchased 38,023 shares in the company on Jan. 22 at $5.26 per share.


Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine

Multikine is a cancer immunotherapy, which has significantly improved survival in head and neck cancer patients during global Phase 3 trials.

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.


Cel-Sci Stock Slips After Public Offering: Retail's Neutral

The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>The biotech firm said it intends to use the gross proceeds for the development of its Multikine cancer drug, which has an Orphan Drug Designation in the U.S.</li><li>This comes after Cel-Sci announced an offering of 6 million shares at $1.2 last month.</li><li>Cel-Sci recently partnered with Amarox for the regulatory approval, commercialization, and distribution of Multikine in Saudi Arabia.</li></ul>Shares of Cel-Sci Corp. (CVM) slumped more than 7% in pre-market trading on Monday, with the stock tracking its fifth straight session of decline, after the biotech firm announced a second share offering just over a month.<h2 class="st-heading-2">CVM Set To Raise Nearly $10M In A Month</h2>Cel-Sci priced a best-efforts public offering of 2.5 million shares of common stock at $1 per share, aiming to raise gross proceeds of roughly $2.5 million. The clinical-stage immunotherapy company said the offering is expected to close on June 16. The offer price is a 7.4% discount to the stock’s closing price on Friday.The latest fundraising follows a larger offering announced in May, when Cel-Sci priced 6 million shares at $1.20 per share, generating expected gross proceeds of about $7.2 million.The company plans to use the proceeds from both stock offerings to advance the development of Multikine, its lead cancer immunotherapy candidate, and for general corporate and working capital needs.<h2 class="st-heading-2">What Is Multikine?</h2>Multikine is an injectable immunotherapy for patients with newly diagnosed head and neck cancer. Cel-Sci said Phase 3 trial results showed the treatment increased the five-year survival rate to 73% from 45% and reduced the risk of death to 27% from 55%, compared with standard treatment alone.The therapy has been given to more than 740 patients and has received Orphan Drug Designation from the FDA.Cel-Sci recently partnered with Amarox to obtain regulatory approval, commercialize, and distribute Multikine in Saudi Arabia. The agreement could later expand to other Gulf countries, including the UAE, Qatar, Kuwait, Bahrain, and Oman.<h2 class="st-heading-2">What Do Traders Think Of CVM?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CVM">CVM</a> on Stocktwits trended in the ‘neutral’ territory over the past 24 hours.One user called the capital raise “really strange.”<stembedurl>https://stocktwits.com/DeepThought/message/656430727</stembedurl>The stock has been under heavy selling pressure so far in 2026, tanking more than 77%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/mu-stock-leads-memory-chip-rally-amid-iran-relief-dram-surges-6-as-sk-hynix-samsung-gain/cZKfXv4R7dq">MU Stock Leads Memory Chip Rally Amid Iran Relief – DRAM Surges 6% As SK Hynix, Samsung Gain</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cel-Sci logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cel-Sci Corp

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.50
Prev Close	$1.60
Open	$1.56
Dividend Yield	0.00%
50-Day Moving Average	$1.70
Beta	1.07
Avg. Volume	127,544.66
PE Ratio	-0.58

52-Week High	$7.80
52-Week Low	$0.89
Market Capitalization	$26.38M
EPS (Annual)	-$6.27
Price to Book	2.41
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

CVM Fundamentals